APR 10, 2021 7:44 AM PDT

Administration of this immune-stimulating drug pre-surgery could help pancreatic cancer patients

New findings support the administration of a CD40 immune-stimulating drug to early-stage pancreatic cancer patients in advance of surgery. The study, led by researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania, suggests that pre-treatment CD40 administration could impede progression and later metastasis of cancer. 

The team conducted the phase 1b clinical trial at the ACC, Fred Hutchinson Cancer Research Center at the University of Washington, Case Western Reserve University, and Johns Hopkins University. They gathered data from 16 patients who received the CD40 agonist selicrelumab prior to surgery; they also obtained data from a control group of patients who did not receive the treatment. CD40 works by activating antigen-presenting cells, like dendritic cells, to ultimately change the tumor microenvironment from “poor” to “rich”. 

The team found that in the patients who received CD40, 82% of their tumors were T-cell enriched, whereas only 37% of untreated tumors were T-cell enriched. Patients receiving CD40  has a median disease-free survival of 13.8 months and median overall survival of 23.4 months, while half of the original group were alive at a median of 20 months after surgery. 

The study was presented by Katelyn T. Byrne, PhD, at a plenary session at the American Association for Cancer Research annual meeting. Byrne is an instructor of Medicine in the division of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania. 

"Many patients with early-stage disease undergo surgery and adjuvant chemotherapy. But it's often not enough to slow or stop cancer," Byrne said. "Our data support the idea that you can do interventions upfront to activate a targeted immune response at the tumor site -- which was unheard of five years ago for pancreatic cancer -- even before you take it out. This is a first step in building a backbone for immunotherapy interventions in pancreatic cancer.”

The researchers say that their study provides support for further investigations into CD40 therapy combined with other cancer treatments. "We're starting to turn the tide," concludes senior author Robert H. Vonderheide, MD, DPhil, director of the ACC. "This latest study adds to growing evidence that therapies such as CD40 before surgery can trigger an immune response in patients, which is the biggest hurdle we've faced. We're excited to see how the next generation of CD40 trials will take us even closer to better treatments."

Sources: University of Pennsylvania, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUL 12, 2021
Cell & Molecular Biology
A Molecule From the Gut Microbiome May Fight Tumors
JUL 12, 2021
A Molecule From the Gut Microbiome May Fight Tumors
The more we learn abut the gut microbiome, the more it seems that the microorganisms in our gastrointestinal tracts can ...
JUL 23, 2021
Cancer
New Drug Eradicates Breast Cancer Tumors in Days
JUL 23, 2021
New Drug Eradicates Breast Cancer Tumors in Days
A new drug can kill between 95 and 100% of cancer cells in mice with human estrogen-receptor-positive breast cancer. The ...
AUG 18, 2021
Technology
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
AUG 18, 2021
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
All cells in a tumor share some genetic similarities, but also have key differences, often hindering effective treatment ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 13, 2021
Cancer
Fat Loss can Predict Gastric Cancer Survival
SEP 13, 2021
Fat Loss can Predict Gastric Cancer Survival
Cancer cachexia is a metabolic disorder in cancer patients experiencing uncontrolled weight loss.  While cancer cac ...
SEP 27, 2021
Cell & Molecular Biology
Optical Imaging in Tissue with Near-Infrared Dyes
SEP 27, 2021
Optical Imaging in Tissue with Near-Infrared Dyes
Optical Imaging in Tissue with Near-Infrared Dyes Written By Christopher Pratt, PhD   Go Long to See Deeper Imaging ...
Loading Comments...